Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CFO Sells $80,800.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $8.08, for a total transaction of $80,800.00. Following the completion of the sale, the chief financial officer now directly owns 35,190 shares of the company’s stock, valued at $284,335.20. This represents a 22.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zynex Stock Performance

Zynex stock opened at $7.94 on Friday. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The firm has a market cap of $252.89 million, a P/E ratio of 52.93 and a beta of 0.49. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77. The firm has a 50-day moving average of $8.25 and a 200-day moving average of $8.61.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. The firm had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business’s revenue was up .1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. Sell-side analysts expect that Zynex, Inc. will post 0.2 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ZYXI. Hotchkis & Wiley Capital Management LLC increased its stake in shares of Zynex by 24.7% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after purchasing an additional 147,770 shares in the last quarter. Millennium Management LLC grew its stake in shares of Zynex by 66.5% in the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after buying an additional 118,615 shares during the last quarter. Renaissance Technologies LLC increased its position in Zynex by 68.7% during the 2nd quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after buying an additional 77,300 shares in the last quarter. GSA Capital Partners LLP raised its stake in Zynex by 72.7% during the third quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock valued at $652,000 after buying an additional 33,649 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Zynex by 6.7% in the third quarter. Geode Capital Management LLC now owns 425,509 shares of the company’s stock worth $3,473,000 after acquiring an additional 26,774 shares in the last quarter. 29.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. HC Wainwright increased their target price on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada cut their target price on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.